Crosstalk Between Immunity System Cells and Pancreas. Transformation of Stem Cells Used in the 3D Bioprinting Process as a Personalized Treatment Method for Type 1 Diabetes

Niedźwiedzka-Rystwej, Paulina; Wołącewicz, Mikołaj; Cywoniuk, Piotr; Klak, Marta; Wszoła, Michał

doi:10.1007/s00005-020-00578-2

Cited by 5 publications

(5 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The susceptibility and resistance to T1D are caused by, among other things, the human HLA antigen complex, which is located on chromosome 6—primarily HLA class II [ 25 ]. Apart from genetic factors, age and sex, the so-called environmental risk factors are more and more often mentioned, acting early in life on genetically susceptible people, may trigger adverse immune processes [ 24 , 26 ].…”

Section: Structure Of the Pancreas And The Role Of Individual Cellsmentioning

confidence: 99%

“…Although molecular pathomechanism standing behind T1D remains not fully understood, several works point to disturbance in human leukocyte antigen (HLA) system expression in T1D patients [ 26 , 168 , 169 ]. HLA (or major histocompatibility complex, MHC) is a cluster of surface proteins pivotal in proper recognition of antigens by distinct types of lymphocytes T. All HLA -coding genes are located on chromosome 6 and are highly polymorphic which reflects in many variants of particular HLA protein which, in turn, occur in multiple combinations on cells [ 170 , 171 , 172 ].…”

Section: Immune-related Aspects Of T1d and Possible Applications Of Stem Cells In Therapymentioning

confidence: 99%

See 1 more Smart Citation

Stem Cells as a Source of Pancreatic Cells for Production of 3D Bioprinted Bionic Pancreas in the Treatment of Type 1 Diabetes

Wszoła¹,

Nitarska²,

Cywoniuk³

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

Type 1 diabetes (T1D) is the third most common autoimmune disease which develops due to genetic and environmental risk factors. Often, intensive insulin therapy is insufficient, and patients require a pancreas or pancreatic islets transplant. However, both solutions are associated with many possible complications, including graft rejection. The best approach seems to be a donor-independent T1D treatment strategy based on human stem cells cultured in vitro and differentiated into insulin and glucagon-producing cells (β and α cells, respectively). Both types of cells can then be incorporated into the bio-ink used for 3D printing of the bionic pancreas, which can be transplanted into T1D patients to restore glucose homeostasis. The aim of this review is to summarize current knowledge about stem cells sources and their transformation into key pancreatic cells. Last, but not least, we comment on possible solutions of post-transplant immune response triggered stem cell-derived pancreatic cells and their potential control mechanisms.

show abstract

Section: Structure Of the Pancreas And The Role Of Individual Cellsmentioning

confidence: 99%

Section: Immune-related Aspects Of T1d and Possible Applications Of Stem Cells In Therapymentioning

confidence: 99%

Stem Cells as a Source of Pancreatic Cells for Production of 3D Bioprinted Bionic Pancreas in the Treatment of Type 1 Diabetes

Wszoła¹,

Nitarska²,

Cywoniuk³

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…Growing evidence suggests that aberrations in cell-to-cell communications within the pancreatic microenvironment play a critical role in the pathophysiological responses of the pancreas to diverse stimuli [ 10 ]. In particular, this review will particularly emphasize the role of immune cells, notably macrophages, in modulating the cellular crosstalk in the pancreatic microenvironment, which, in turn leads, to a disruption of the homeostasis within the pancreatic milieu [ 11 , 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

“…In particular, this review will particularly emphasize the role of immune cells, notably macrophages, in modulating the cellular crosstalk in the pancreatic microenvironment, which, in turn leads, to a disruption of the homeostasis within the pancreatic milieu [ 11 , 12 , 13 ]. This dysregulation is increasingly recognized as a significant factor in the pathogenesis of several pancreatic diseases, such as pancreatitis, diabetes, and cancer [ 10 , 14 , 15 ]. This review aims to summarize current findings and offer insights into the mechanistic view of macrophage-mediated alteration and its regulators in the pathogenesis of pancreatic diseases.…”

Section: Introductionmentioning

confidence: 99%

The Pivotal Role of Macrophages in the Pathogenesis of Pancreatic Diseases

Ryu,

Lee

2024

IJMS

View full text Add to dashboard Cite

The pancreas is an organ with both exocrine and endocrine functions, comprising a highly organized and complex tissue microenvironment composed of diverse cellular and non-cellular components. The impairment of microenvironmental homeostasis, mediated by the dysregulation of cell-to-cell crosstalk, can lead to pancreatic diseases such as pancreatitis, diabetes, and pancreatic cancer. Macrophages, key immune effector cells, can dynamically modulate their polarization status between pro-inflammatory (M1) and anti-inflammatory (M2) modes, critically influencing the homeostasis of the pancreatic microenvironment and thus playing a pivotal role in the pathogenesis of the pancreatic disease. This review aims to summarize current findings and provide detailed mechanistic insights into how alterations mediated by macrophage polarization contribute to the pathogenesis of pancreatic disorders. By analyzing current research comprehensively, this article endeavors to deepen our mechanistic understanding of regulatory molecules that affect macrophage polarity and the intricate crosstalk that regulates pancreatic function within the microenvironment, thereby facilitating the development of innovative therapeutic strategies that target perturbations in the pancreatic microenvironment.

show abstract

“…Novel strategies for preventing and managing T1DM are investigated [8,9]. One re search direction in this field is antigen vaccination (with oral insulin or peptides) and stem-cell-based replacement therapies [10] to prevent and reverse diabetes autoimmunity FDA approved in November 2022 the first drug-Tzield (teplizumab-mzwv) injectionthat can delay the onset of T1DM [11][12][13], resulting in years of disease remission [14]. Data also suggest that verapamil and glucagon-like peptide-1 receptor agonists could act as beta cell protective agents (in stress conditions).…”

Section: Introductionmentioning

confidence: 99%

Current Technologies for Managing Type 1 Diabetes Mellitus and Their Impact on Quality of Life—A Narrative Review

Elian,

Popovici,

Ozon

et al. 2023

Life

View full text Add to dashboard Cite

Type 1 diabetes mellitus is a chronic autoimmune disease that affects millions of people and generates high healthcare costs due to frequent complications when inappropriately managed. Our paper aimed to review the latest technologies used in T1DM management for better glycemic control and their impact on daily life for people with diabetes. Continuous glucose monitoring systems provide a better understanding of daily glycemic variations for children and adults and can be easily used. These systems diminish diabetes distress and improve diabetes control by decreasing hypoglycemia. Continuous subcutaneous insulin infusions have proven their benefits in selected patients. There is a tendency to use more complex systems, such as hybrid closed-loop systems that can modulate insulin infusion based on glycemic readings and artificial intelligence-based algorithms. It can help people manage the burdens associated with T1DM management, such as fear of hypoglycemia, exercising, and long-term complications. The future is promising and aims to develop more complex ways of automated control of glycemic levels to diminish the distress of individuals living with diabetes.

show abstract

Crosstalk Between Immunity System Cells and Pancreas. Transformation of Stem Cells Used in the 3D Bioprinting Process as a Personalized Treatment Method for Type 1 Diabetes

Cited by 5 publications

References 86 publications

Stem Cells as a Source of Pancreatic Cells for Production of 3D Bioprinted Bionic Pancreas in the Treatment of Type 1 Diabetes

Stem Cells as a Source of Pancreatic Cells for Production of 3D Bioprinted Bionic Pancreas in the Treatment of Type 1 Diabetes

The Pivotal Role of Macrophages in the Pathogenesis of Pancreatic Diseases

Current Technologies for Managing Type 1 Diabetes Mellitus and Their Impact on Quality of Life—A Narrative Review

Contact Info

Product

Resources

About